PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicineMUKHOPADHYAY, A; CURTIN, N; PLUMMER, R et al.BJOG (Oxford. Print). 2011, Vol 118, Num 4, pp 429-432, issn 1470-0328, 4 p.Article

Androgen-related expression of G-proteins in ovarian cancerSHEACH, L. A; ADENEY, E. M; KUCUKMETIN, A et al.British journal of cancer. 2009, Vol 101, Num 3, pp 498-503, issn 0007-0920, 6 p.Article

Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcomaGALAAL, K; KEW, F. M; TAM, K. F et al.European journal of obstetrics, gynecology, and reproductive biology. 2009, Vol 143, Num 2, pp 88-92, issn 0301-2115, 5 p.Article

Intra-operative frozen section analysis for suspected early-stage ovarian cancer: 11 years of Gateshead Cancer Centre experienceCROSS, P. A; NAIK, R; KUCUKMETIN, A et al.BJOG (Oxford. Print). 2012, Vol 119, Num 2, pp 194-201, issn 1470-0328, 8 p.Article

Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancerWILKINSON, S. J; KUCUKMETIN, A; CROSS, P et al.Human pathology. 2008, Vol 39, Num 8, pp 1197-1204, issn 0046-8177, 8 p.Article

The human ovarian surface epithelium is an androgen responsive tissueEDMONDSON, R. J; MONAGHAN, J. M; DAVIES, B. R et al.British journal of cancer. 2002, Vol 86, Num 6, pp 879-885, issn 0007-0920Article